GRIA Gene Expression in Schizophrenia: A Participant-Level Meta-Analysis
Alpha Psychiatry · 21.05.2026 · 27 (3)
DOI: 10.31083/ap46200 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Alpha Psychiatry, online erschienen am 21.05.2026. Verfasst von Adan Baumel und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, 6997801 Tel Aviv, Israel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Schizophrenia is a complex mental disorder with an estimated heritability of 80%, yet its underlying pathophysiology remains poorly understood. Emerging evidence implicates the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) glutamate receptor—a key player in fast excitatory synaptic transmission, encoded by Glutamate Ionotropic Receptor AMPA Type Subunits 1-4 (GRIA1-4)—in the disorder's pathophysiology. However, findings from postmortem brain samples regarding GRIA1-4 expression have been inconsistent. This study aimed to systematically evaluate the differential expression of GRIA1-4 genes in schizophrenia by integrating transcriptomic data from postmortem brain tissue and patient-derived cerebral organoids.
Methods
We conducted a participant-level meta-analysis of seven postmortem brain sample datasets (n = 295; 151 schizophrenia, 144 controls) and analyzed an independent organoid dataset (n = 16). Expression differences between schizophrenia and control samples were quantified using Hedges' g under a random-effects model, with heterogeneity assessed using the I2 statistic.
Results
Our analysis revealed significant downregulation of all four GRIA genes (GRIA1-4) in postmortem brain tissue from individuals with schizophrenia, with the effect concentrated in a subgroup of patients. No substantial heterogeneity was attributable to differences in brain regions or measurement platforms. Consistent downregulation of GRIA1-3 was observed in patient-derived cerebral organoids, which model early neurodevelopmental stages.
Conclusions
Our findings highlight AMPA receptor dysfunction as a potential contributor to schizophrenia pathophysiology in a subgroup of patients, consistent with the broader role of glutamatergic signaling disruption in this disorder. The convergent evidence from postmortem brain tissue and developmental models underscores the need for further investigation of GRIA genes as potential biomarkers for patient stratification and as therapeutic targets. While further study is needed to understand the functional consequences of our findings, such insights may inform the development of personalized treatment strategies targeting glutamatergic dysfunction in schizophrenia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, 6997801 Tel Aviv, Israel.
- Department of Physics of Complex Systems, Weizmann Institute of Science, 7610001 Rehovot, Israel.
- Adult Inpatient Ward, Shalvata Mental Health Center, 45100 Hod Hasharon, Israel.
ORCID-Profile: Adan Baumel, Libi Hertzberg
Zitieren
APA
Baumel, A., Yitzhaky, A., & Hertzberg, L. (2026). GRIA Gene Expression in Schizophrenia: A Participant-Level Meta-Analysis. Alpha Psychiatry, 27(3). https://doi.org/10.31083/ap46200
Vancouver
Baumel A, Yitzhaky A, Hertzberg L. GRIA Gene Expression in Schizophrenia: A Participant-Level Meta-Analysis. Alpha Psychiatry. 2026;27(3). doi:10.31083/ap46200
BibTeX
@article{Baumel2026,
author = {Baumel, Adan and Yitzhaky, Assif and Hertzberg, Libi},
title = {GRIA Gene Expression in Schizophrenia: A Participant-Level Meta-Analysis},
journal = {Alpha Psychiatry},
year = {2026},
volume = {27},
number = {3},
doi = {10.31083/ap46200}
}
EUVIMED